AI assistant
BPH ENERGY LTD — Capital/Financing Update 2020
Jan 27, 2020
64555_rns_2020-01-27_1b867381-d9b4-4b59-8ff9-ccd0b5db5262.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [271 x 99] intentionally omitted <==
28 01 2020
Companies Announcement Office ASX Limited Exchange Centre Level 4, 20 Bridge Street Sydney, NSW 2000
Dear Sir/Madam
ASX Market Release – Patagonia Genetics
BPH INVESTEE PATAGONIA GENETICS EXECUTES JOINT VENTURE AGREEMENT WITH ISRAELI BASED RESEARCH GROUP 'BIO-SCIENCES PHARMA LTD.
BPH Energy Limited (ASX: BPH) ( BPH ) is pleased to announce its investee Patagonia Genetics has recently executed a joint venture agreement with Israeli based research group Bio-Sciences Pharma Ltd (BSP), a subsidiary of Impact NRS (NRS).
Further details are attached.
David Breeze Executive Director
BPH Energy Limited ACN 95 912 002 PO Box 317, North Perth, Western Australia 6906 14 View Street, North Perth, Western Australia 6006
[email protected] www.bphenergy.com.au T: +61 8 9328 8366 F: +61 8 9328 8733
==> picture [596 x 174] intentionally omitted <==
28 JANUARY 2020
PATAGONIA GENETICS EXECUTES JOINT VENTURE AGREEMENT WITH ISRAELI BASED RESEARCH GROUP 'BIOSCIENCES PHARMA LTD.'
Patagonia Genetics SpA (Patagonia) is pleased to advise that it has executed a joint venture agreement with Israeli based research group Bio-Sciences Pharma Ltd (BSP), a subsidiary of Impact NRS (NRS).
HIGHLIGHTS
-
Joint Venture executed with innovative science and technology group Bio-Sciences Pharma Ltd, a company at the forefront of medical cannabis research in Israel;
-
Ninety-four (94) of Patagonia Genetics' cultivars to be studied for their medicinal properties; &
-
Agreement to co-commercialize any cultivars of interest.
Patagonia has recently executed a joint venture agreement with BSP, a subsidiary of NRS to expedite the cultivation, testing and cataloging of its genetic collection, as well as the commercialization of any genetics that show unique medicinal properties.
Under the terms of the agreement Patagonia will supply BSP with ninety-four (94) cultivars to conduct an eighteen (18) month study, as well as obtain the necessary phytosanitary certificates to permit their import into Israel.
The purpose of the study is to research how each of more than 100 active compounds found in cannabis can interact within the Cannabis plant. Once individual compounds and their effects have been characterized, gene expression in plants can be modified to produce the desired cannabinoids as well as negate any negative side effect.
Genetic samples will be propagated under BSP's cannabis cultivation license in Israel. A Certificate of Analysis (CoA) will be produced for each cultivar quantifying the cannabinoid and terpene profiles, including Tetrahydrocannabinol (THC) and cannabidiol (CBD).
At the end of the study, both Patagonia and BSP will review the results and look to co-commercialize any cultivars of interest.
Patagonia's in-country manager Miguel Serrano commented that:
"This is a landmark deal for Patagonia Genetics. We will finally be able to explore the potential of our unique genetic collection. With up to 94 cultivars to be propagated and lab tested this deal saves Patagonia several years in research and development and significant capital expenditure. Patagonia considers Israel is the leading authority on medicinal cannabis research and is excited to collaborate with BSP in delivering a designer cannabis product. Having a catalogue of up to 94 lab tested cultivars will position Patagonia as one of the most diversified seed banks in the cannabis and hemp space."
Q 9/204 Alice St, Brisbane QLD 4000, Australia
Q Av. Vitacura 2771, Oficina 503, Las Condes, Santiago
==> picture [595 x 13] intentionally omitted <==
==> picture [110 x 106] intentionally omitted <==
----- Start of picture text ----- PGONIA----- End of picture text -----
ABOUT BIO-SCIENCES PHARMA LTD
Bio-Sciences Pharma is a Cannabis Cell Transformation Platform with unique capabilities combining cutting edge gene editing tools with advanced breeding technologies. The company implements a systemic cell transformation system to isolate each of the approximately 100 active compounds in a reference cannabis specie to determine their independent and synergistic bioactivity. Upon completion, this system can be used to create proprietary nontransgenic gene-edited varieties that bind with specific efficacious bioactive sites in human and disease targets without adverse/undesirable traits.
The company owns over 1000 square meters of growing facilities comprising approximately 10,000 seedlings at all times, and over 200 square meters of state-of-the-art laboratories supporting metabolomics and tissue culture research, containing cutting-edge chemical and analytical equipment and tools.
ABOUT IMPACT NRS
Impact NRS (NRS) is an innovations company at the forefront of science and technology. Working with leading, interdisciplinary scientists, the Company deploys cutting edge precision molecular biology tools with proprietary and novel statistical prediction algorithms to create and commercialize visionary integrated solutions to critical global challenges in health, wellness and sustainable development.
Q 9/204 Alice St, Brisbane QLD 4000, Australia
Q Av. Vitacura 2771, Oficina 503, Las Condes, Santiago
==> picture [595 x 13] intentionally omitted <==
==> picture [112 x 106] intentionally omitted <==
BUSINESS DETAILS
Patagonia Genetics Pty Ltd (ACN 632 142 333) Address: 9/204 Alice St, Brisbane, QLD 4000 Website: www.patagoniagenetics.com Email: [email protected]
Patagonia Genetics SpA (RUT 76.923.997-9) Address: Av. Vitacura 2771, Oficina 503, Las Condes, Santiago.
For further information please contact:
==> picture [81 x 80] intentionally omitted <==
Matthew Critchley
Managing Director Patagonia Genetics Pty Ltd (ACN 632 142 333) E: [email protected] M: +61 400 112 816
About Patagonia Genetics
Patagonia Genetics Pty Ltd (ACN 632 142 333) is a craft cannabis company with 100% owned subsidiary Patagonia Genetics SpA (RUT 76.923.997-9) based in Patagonia, Chile boasting a genetic collection of over 300 unique cannabis and hemp strains, carefully collected from industrial hemp cultivations of the late 1980's. Patagonia Genetics intends to cultivate and manufacture a range of medicinal cannabis products to be sold throughout South America, as well as supply high grade genetics to international markets.
About Bio-Sciences Pharma Ltd
Bio-Sciences Pharma Ltd (Identity Card Number 515817401) with legal domicile in Tel Aviv, Israel is a subsidiary of Impact NRS (NRS). NRS is an innovations company at the forefront of science and technology. Working with leading, interdisciplinary scientists, the Company deploys cutting edge precision molecular biology tools with proprietary and novel statistical prediction algorithms to create and commercialize visionary integrated solutions to critical global challenges in health, wellness and sustainable development.
Q 9/204 Alice St, Brisbane QLD 4000, Australia
Q Av. Vitacura 2771, Oficina 503, Las Condes, Santiago